Triple-Negative Breast Cancer Treatment Algorithm
Panelists discuss how triple-negative breast cancer (TNBC) treatment typically follows a multimodal approach: neoadjuvant chemotherapy for tumors larger than 2 cm or node-positive disease, followed by surgery (lumpectomy or mastectomy). Postsurgery radiation therapy is recommended based on staging. For early-stage TNBC, adjuvant platinum-based chemotherapy and immunotherapy with pembrolizumab may be considered. Metastatic TNBC may receive targeted therapy (PARP inhibitors for BRCA mutations) or immunotherapy based on PD-L1 status.
EP. 1: Early-Stage Triple-Negative Breast Cancer
February 10th 2025Panelists discuss how triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by the absence of 3 key receptors: estrogen receptor, progesterone receptor, and HER2 protein. TNBC tends to grow and spread faster than other breast cancer types, presenting unique treatment challenges since common targeted therapies like hormone therapy and HER2-targeted treatments are ineffective. Standard treatment primarily relies on chemotherapy, surgery, and radiation.
EP. 2: Locally Advanced Triple-Negative Breast Cancer
February 10th 2025Panelists discuss how locally advanced triple-negative breast cancer (LATNBC) is an aggressive breast cancer subtype characterized by absence of estrogen receptor, progesterone receptor, and HER2 protein expression. It presents with large tumors and/or extensive lymph node involvement without distant metastasis. Treatment typically involves neoadjuvant chemotherapy followed by surgery and radiation.
EP. 3: Navigation of Triple-Negative Breast Cancer Treatment Toxicities
February 10th 2025Panelists discusses how triple-negative breast cancer (TNBC) treatment toxicities require careful monitoring and management. Common adverse effects include fatigue, nausea, hair loss, neuropathy from chemotherapy, and radiation-induced skin changes. Health care teams employ preventive strategies, dose modifications, and supportive care to minimize complications while maintaining treatment efficacy.
EP. 4: Approach to Metastatic Disease
February 10th 2025Panelists discuss how the approach to metastatic disease focuses on systemic therapy, as cancer has spread beyond its primary site. Treatment typically combines targeted therapy, immunotherapy, chemotherapy, and/or hormonal therapy based on cancer type and molecular profile. Goals shift toward extending survival, controlling symptoms, and maintaining quality of life rather than cure. Regular monitoring of treatment response and adverse effects guides ongoing care decisions.
EP. 5: Clinical Pros of Sacituzumab and T-DXd
February 10th 2025Panelists discuss how sacituzumab shows significant efficacy in triple-negative breast cancer, with improved progression-free and overall survival. It demonstrates particular benefit in pretreated patients and brain metastases cases. Trastuzumab deruxtecan (T-DXd) excels in HER2-positive breast cancer treatment, showing remarkable response rates and survival benefits, including in patients with brain metastases and those who progressed on prior therapies.
